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We recently published a protocol to vitrify human articular cartilage and a method of cryoprotectant
removal in preparation for transplantation. The current study’s goal was to perform a cryoprotectant
kinetic analysis and theoretically shorten the procedure used to vitrify human articular cartilage. First,
the loading of the cryoprotectants was modeled using Fick’s law of diffusion, and this information was
used to predict the kinetics of cryoprotectant efﬂux after the cartilage sample had been warmed. We
hypothesized that diffusion coefﬁcients obtained from the permeation of individual cryoprotectants into
porcine articular cartilage could be used to provide a reasonable prediction of the cryoprotectant loading
and of the combined cryoprotectant efﬂux from vitriﬁed human articular cartilage. We tested this hy-
pothesis with experimental efﬂux measurements. Osteochondral dowels from three patients were
vitriﬁed, and after warming, the articular cartilage was immersed in 3 mL X-VIVO at 4 C in two
consecutive solutions, each for 24 h, with the solution osmolality recorded at various times. Measured
equilibrium values agreed with theoretical values within a maximum of 15% for all three samples. The
results showed that diffusion coefﬁcients for individual cryoprotectants determined from experiments
with 2-mm thick porcine cartilage can be used to approximate the rate of efﬂux of the combined
cryoprotectants from vitriﬁed human articular cartilage of similar thickness. Finally, Fick’s law of diffu-
sion was used in a computational optimization to shorten the protocol with the constraint of maintaining
the theoretical minimum cryoprotectant concentration needed to achieve vitriﬁcation. The learning
provided by this study will enable future improvements in tissue vitriﬁcation.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Osteoarthritis can be caused by progressive deterioration of
articular cartilage defects/injuries. Current non-operative treat-
ments do not affect the disease process while surgical treatments
such as drilling, microfracture, autologous chondrocyte implanta-
tion, and matrix associated chondrocyte implantation have been
unable to restore the normal articular cartilage architecture.
Autologous osteochondral grafting can be done using multiple
plugs from a different, less weight-bearing part of the joint
(mosaicplasty [16]) but is limited by the amount of availableand Materials Engineering,
liott).
Inc. This is an open access article uarticular cartilage to transplant and the risk of donor site morbidity
[25]. Alternatively, fresh osteochondral allografting has shown
good long term results in the management of large joint defects
[7,15]. Unfortunately, fresh osteochondral allografting has become
impractical due to required testing for infectious diseases and
regulatory clearance before the transplantation of non-essential
organs. Prolonged hypothermic storage of allografts at 4 C has
evolved to provide a storage technique prior to transplantation that
enables appropriate testing. Unfortunately, storage at 4 C for
greater than 14 days has been shown to signiﬁcantly decrease the
cellular and physical properties of articular cartilage [8,34] and
maximum storage at this temperature is 28e42 days. Thus, a long-
term storage technique for articular cartilage may improve oppor-
tunities for osteochondral allografting and result in further
improvement in osteochondral allografting results.
Long-term banking of biologic tissues can be accomplishednder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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articular cartilage cryopreservation [3]. Brieﬂy, classic cryopreser-
vation techniques have typically used low concentrations of cryo-
protectants and controlled freezing. However, many attempts at
cryopreserving articular cartilage using this method failed due to
cell death and matrix distortion [18,19,28]. Vitriﬁcation, the for-
mation of an amorphous solid from an aqueous solution, has the
potential to maintain matrix integrity while preserving cell
viability. Preliminary studies have been performed to determine
toxicity and toxicity interactions of cryoprotectants to human and
porcine articular chondrocytes [6,22], permeation kinetics of
cryoprotectants in articular cartilage [4,21,31], and cryoprotectant
contributions to vitriﬁability and vitriﬁability interactions of
commonly used cryoprotectants [33]. This information was used to
successfully vitrify full-thickness, intact human articular cartilage
on a bone base with high cell viability and preserved cellular
metabolism and function [20], making long-term clinical banking
of osteochondral tissue possible.
Vitriﬁcation involves the use of very high concentrations of
cryoprotectants and rapid cooling rates [13] to cool the tissue below
the glass transition temperature where biological and chemical
reactions cease, thereby preventing cell deterioration in storage.
The process of vitriﬁcation avoids the intracellular and extracellular
formation of ice that is known to damage tissues [29], but the high
concentrations of cryoprotectants used to vitrify tissues can also
result in signiﬁcant cellular toxicity. The interplay between tem-
perature, mass transfer, and cytotoxicity was modeled by Lawson
et al. [24]. The thermodynamics behind the process of vitriﬁcation
was summarized by Wowk [35], examining both equilibrium and
non-equilibrium vitriﬁcation methods and the physical mecha-
nisms that underlie the formation of the amorphous solid. Past
studies have also examined various cryoprotectant solutions, such
as VS55, VS83, and DP6 [11,27], for the vitriﬁcation of animal
articular cartilage [9,26] and tissue-engineered cartilage [14,23].
VS55 and VS83 are vitriﬁcation solutions containing a total cryo-
protectant concentration of 55% (8.4 M) and 83% (12.6 M),
respectively, consisting of dimethyl sulfoxide, formamide, and
propylene glycol, while DP6 does not contain formamide and has a
lower total cryoprotectant concentration of 6 M. As a result of the
possibility for cellular damage due to toxicity, it is important to
remove the cryoprotectants rapidly from the vitriﬁed tissue upon
warming.
In the clinical scenario, it is essential to remove virtually all
cryoprotectants to mitigate local and systemic toxicity. Most
recently, a clinical protocol was developed to remove cryoprotec-
tants from osteochondral dowels vitriﬁed using our 6.5 M protocol
by multiple immersions in X-VIVO removal solution [36]. One
objective of the current study was to investigate the kinetics of
cryoprotectant efﬂux from intact articular cartilage after it was
vitriﬁed using our established protocol [20] by measuring the
change in osmolality of the removal solution over extended periods
of time. The results were compared to a theoretical model predic-
tion using Fick’s law of diffusion with previously determined
diffusion coefﬁcients for individual cryoprotectants in 2-mm thick
porcine articular cartilage [4,21] and an assumption of no interac-
tion between cryoprotectants. We hypothesized that even with
various assumptions and simpliﬁcationsmadewith the use of Fick’s
law, diffusion coefﬁcients previously obtained for the permeation
of individual cryoprotectants into porcine articular cartilage could
be used to provide a reasonable prediction of the efﬂux of com-
bined cryoprotectants from vitriﬁed human articular cartilage.
Once the model was veriﬁed for cryoprotectant efﬂux calcula-
tions, a further objective was to understand the spatial distribution
of individual cryoprotectants at the end of each loading step in our
published protocol and use this insight to propose a shorter timefor loading the cryoprotectants into the cartilage. With the shorter
loading time, the minimum cryoprotectant concentrations needed
for successful vitriﬁcation are still achieved within the cartilage
matrix.
2. Experimental methods & materials
After ethical approval (University of Alberta Human Research
Ethics Board), a hand-held coring device was used to obtain 10-mm
diameter osteochondral dowels (full thickness articular cartilage on
a bone base) from the non-damaged, weight bearing portion of
distal femoral condyles obtained from biological discards from
patients undergoing total knee arthroplasty in Edmonton, Canada.
All osteochondral dowels used for this experiment appeared
grossly normal to visual inspection. Patient information including
age, gender, weight, height, medical diseases, and smoking status
was recorded. Osteochondral dowels were placed in a Dulbecco’s
Phosphate Buffer Saline (PBS) solution (pH 7.1) until they were
either vitriﬁed (experimental group) or used as controls.
Osteochondral dowels were vitriﬁed using our established
protocol that results in an intended total minimum cryoprotectant
concentration of 6.5 M at the boneecartilage junction by the end of
the protocol. This established protocol consists of four loading steps
by immersion in solutions of: i) 6 M dimethyl sulfoxide (Me2SO) for
1 h 30 min at 0 C, ii) 6 M glycerol and 2.4375 M Me2SO for 3 h
40 min at 0 C, iii) 6 M propylene glycol (PG), 1.625 M glycerol, and
2.4375 MMe2SO for 3 h at 10 C, and iv) 6 M ethylene glycol (EG),
0.8125 M PG, 1.625 M glycerol, and 2.4375 M Me2SO for 1 h
20 min at 15 C [20]. Three vitriﬁed osteochondral dowel samples
from three patients were selected randomly for the experiment.
Tubes containing the vitriﬁed dowels were removed from liquid
nitrogen and placed in a water bath at 37 C until the solidiﬁed
storage solution melted. The tubes were left in the water bath until
used (time range: 5e7 min). The dowels were blot-dried using
Kimwipe tissue (Kimberly-Clark, Roswell, GA), and the articular
cartilage portion of each dowel was removed from its bone base
using a scalpel. The volume of each articular cartilage disc was
calculated using the average of thicknesses measured at three
different locations.
In the experimental group, three 10-mm diameter articular
cartilage discs from three males aged 64, 70 and 76 years were each
immersed sequentially in two 15 mL conical centrifuge tubes (each
containing 3 mL X-VIVO (Lonza, USA) at 4 C) for 24 h. The osmo-
lality of a 50 ml sample of the removal solutionwasmeasuredwith a
‘mOSMETTE’micro-osmometer (Precision Systems, Natick, MA) at 0,
1, 3, 5, 10, 30, 60, 120, 180, 240, 300, 360, and 1440 min for the ﬁrst
immersion, and at 0, 1, 3, 5, 10, 30, 60, 120, and 1440 min for the
second immersion. The extracted solution was replaced after each
reading. A magnetic stirring bar (size equal to, or smaller than,
8  1.5 mm) was placed at the bottom of each tube to aid solution
mixing with the tubes kept in a plastic rack sitting on the stirrer.
After 24 h in the ﬁrst tube, the articular cartilage disc was removed
and dried, weighed and immersed in the second conical centrifuge
tube containing 3 mL X-VIVO. Again, the change in osmolality was
repeatedly measured as described previously. The articular carti-
lage discs were dried and weighed after the second immersion.
The experimental controls consisted of two fresh 10-mm
diameter articular cartilage discs from two different donors (two
females both aged 73 years). The controls were immersed in 3 mL
X-VIVO without cryoprotectant loading using the same experi-
mental protocol described for the experimental group with
osmolality measurements at 0, 1, 3, 5, 10, 30, 60, and 1440 min.
Unlike their experimental counterparts, the control articular
cartilage discs were immersed in 3 mL X-VIVO only once (instead of
twice) because there was minimal change in solution osmolality.
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minus original removal solution osmolality) was normalized to the
calculated volume of the articular cartilage disc (DOsmolality/mL
dowel).
3. Governing equations for initial cryoprotectant distribution
To design a theoretical model of cryoprotectant efﬂux, the initial
concentration proﬁle of cryoprotectants over the entire cartilage
thickness is needed, not solely the minimum concentration at the
boneecartilage junction (a criterion used during the design of the
original successful vitriﬁcation protocol [20]). To determine this
concentration proﬁle, Fick’s law of diffusion was used to calculate
the spatial and temporal distribution of each cryoprotectant’s
concentration during the loading steps of the vitriﬁcation process.
The cartilagewas modeled as a cylindrical disc with thickness a and
radius Rc, and a two-dimensional form of Fick’s law was used [10]:
vC
vt
¼ D
 
v2C
vx2
þ v
2C
vr2
þ 1
r
vC
vr
!
; (1)
where C is concentration, t is time, x is position in the axial direc-
tion, r is position in the radial direction, and D is the diffusion co-
efﬁcient. Fig. 1 illustrates the geometry of a cartilage disc attached
to bone for the loading protocol with a 2-D slice through its center.
Concentrationwas calculated over 0  x  a and 0  r  Rc for time
up to the end of each loading step.
For numerical computation, mesh independence was tested,
and a mesh was constructed using a Delaunay triangulation algo-
rithm with a chosen maximum triangle edge length of 0.05 mm.
The built-in MATLAB® (ver. 7.12, Natick, MA, USA) parabolic partial
differential equation solver parabolic() was used to calculate the
concentration proﬁle of each cryoprotectant separately at the end
of every loading step of the protocol. Within the parabolic() func-
tion, the time step is set to achieve a relative error less than 106.
3.1. Initial conditions
For the ﬁrst loading step, it was assumed that the cartilage
initially had a cryoprotectant concentration of 0 M throughout. The
concentration proﬁle of Me2SO in the cartilage after 1 h 30 minwas
then used as the initial condition for the second loading step.
Similarly, the concentration proﬁles of Me2SO and glycerol after 3 h
40minwere taken to be initial conditions for the third loading step,
and ﬁnally the concentration proﬁles of each cryoprotectant after
the 3 h of the third loading step were used as initial conditions forFig. 1. Schematic of a 2-D slice through a cartilage disc with thickness a and radius Rc
attached to bone and immersed in a cryoprotectant solution.the fourth loading step.
3.2. Boundary conditions
The cartilage segment of the osteochondral dowel has four
boundary conditions; the ﬁrst is at the boneecartilage junction
where we assumed no ﬂow of cryoprotectants. That is,
vC
vx

x¼0
¼ 0: (2)
The second boundary condition is at the center of the cylinder
(r¼ 0) where there is no ﬂow due to symmetry. The third boundary
condition is the concentration of the surrounding solution at the
surface of the cartilage in the axial direction (x ¼ a), and the ﬁnal
boundary condition is the concentration of the surrounding solu-
tion at the surface of the cartilage in the radial direction (r ¼ Rc).
3.3. Assumptions
Fick’s law assumes that the solution is ideal and dilute and does
not account for water movement during cryoprotectant diffusion,
which results in an underestimate of actual concentrations
observed during loading when compared to more complex models
of transport mechanisms and experimental data [1,2,5]. Extensive
experimental work would be needed using a large number of
precious human samples in order to implement a more sophisti-
cated model [1,2,5], since parameters such as the permeability of
each cryoprotectant would need to be determined. Fick’s law,
particularly when effective diffusion coefﬁcients are obtained by
ﬁtting actual experimental data (that has water transport occur-
ring) as is the case for the diffusion coefﬁcients used here, provides
useful insight into the general trends of cryoprotectant diffusion
into cartilage and, because it underestimates, provides a means for
conservative design of protocols.
Using the activation energy (Ea) and prefactors (A) determined
in our previous work for porcine cartilage [4,21,31], the diffusion
coefﬁcients to be used for human articular cartilage at the outlined
temperatures can be calculated using the Arrhenius expression
(Equation (3))
D ¼ A exp

Ea
RT

; (3)
where R is the universal gas constant and T is the absolute tem-
perature. Table 1 lists the values of Ea and A for each cryoprotectant
used.
4. Governing equations for efﬂux
Based on the concentration proﬁle of the cryoprotectants
throughout the entire cartilage at the end of the loading protocol, a
theoretical prediction of cryoprotectant efﬂux can be made. Fick’s
law (Equation (1)) is used to determine how the concentration of
each cryoprotectant changes as a function of position for 0  x  a
and 0  r  Rc and as a function of time for 0  t  24 h. The initial
condition for efﬂux is each cryoprotectant’s individual concentra-
tion proﬁle as calculated at the end of the fourth loading step. The
boundary condition at the surface is the concentration of each
cryoprotectant in the surrounding X-VIVO solution. At t ¼ 0, this
concentration is 0 M for each cryoprotectant. The boundary and
initial conditions are updated for each cryoprotectant every 5 min.
Efﬂux predictions were also made for shorter time steps, and 5 min
was chosen to accurately capture the dynamic process of efﬂux
while reducing computational time. The number of moles of each
Table 1
Pre-exponential factor, activation energy, and osmotic virial coefﬁcients of each cryoprotectant from Ref. [4] and Ref. [37].
Cryoprotectant A (m2/s) [4] Ea (kcal/mol) [4] Bi (molal1) [37] Ci (molal2) [37]
Me2SO 2.9895  107 3.9 ± 1.6 0.108 ± 0.005 0
Glycerol 2.0803  106 5.6 ± 1.2 0.023 ± 0.001 0
PG 1.6971  105 6.63 ± 0.04 0.039 ± 0.001 0
EG 1.833  107 3.8 ± 0.7 0.020 ± 0.001 0
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using
nCPA;XVIVOðtÞ ¼ 0:776
Z2p
0
ZRc
0
Za
0
½CCPAðx; r;0Þ
 CCPAðx; r; tÞdx dr dq; (4)
where Rc is the radius of the cartilage, a is the thickness, CCPA de-
notes the concentration proﬁle of each cryoprotectant in the
cartilage, and nCPA;XVIVO is the number of moles of each cryopro-
tectant in the X-VIVO solution. The factor of 0.776 is the percent of
isotonic cartilage volume made up of solution and therefore
capable of holding the cryoprotectants [21,31]. The concentration of
each cryoprotectant in the solutionwas determined by dividing the
moles by the X-VIVO solution volume (3 mL).
In this study, the cartilage disc radius was 5 mm and the
thicknesses for Samples 1, 2, and 3 were 2.98 mm, 2.12 mm, and
2.08 mm, respectively. The diffusion coefﬁcients from our previous
work on porcine articular cartilage for the cryoprotectants at 4 C
(Table 1) were used when solving Equation (1) for efﬂux [4,21,31].
The molalities of the cryoprotectants in the X-VIVO solution were
calculated individually by dividing the moles by the mass of the X-
VIVO (assuming a density of 1 g/mL). After determining the
molality of each cryoprotectant present in the X-VIVO solution, the
form of the osmotic virial equation proposed by Elliott et al. [12,30]
was used to calculate osmolality:
p ¼
X
i
mi þ
X
i
X
j
Bi þ Bj
2
mimj þ
X
i
X
j

X
k

CiCjCk
1=3mimjmk; (5)
where p is the osmolality (osmol/kg solvent), Bn and Cn are solute-
speciﬁc virial coefﬁcients, and mn are molalities (moles solute/kg
solvent) for each of the n components. The solute-speciﬁc virial
coefﬁcients for Me2SO, glycerol, PG, and EG are those recently
updated by Zielinski et al. [37], as listed in Table 1. The osmolality
predicted for each sample was then normalized to the volume of
the articular cartilage disc.Fig. 2. Schematic of a 1-D slab with 2.00-mm thickness and inﬁnite radius.5. Governing equations for optimization
We chose a cartilage sample with a thickness of 2.00 mm as a
representative size for analyzing kinetics towards reducing the
time needed for the vitriﬁcation protocol because this is a common
thickness for femoral articular cartilage. The surface area of artic-
ular cartilage defects can range from 0.5 cm2 to 12 cm2 [17]. Due to
this variation, it is planned to bank entire condyles; therefore we
use a 1-D representation of the cartilage as a slab to optimize the
protocol and ensure successful vitriﬁcation of large area banked
tissue, which will be processed after warming for any surface area
that may be encountered in a clinical setting.
The 1-D representation of Fick’s law isvC
vt
¼ D v
2C
vx2
(6)
where the boundary conditions include the concentration of the
surrounding solution at x ¼ 2.00 mm and the no ﬂow condition at
the boneecartilage junction (x¼ 0mm) given by Equation (2). Fig. 2
illustrates the geometry used for shortening the loading steps of the
vitriﬁcation protocol. The cartilage is modeled as a slab with 2.00-
mm thickness attached to bone placed in a cryoprotectant solution.
Successful vitriﬁcation can only occur if each of the loading steps
takes place at a temperature above the freezing point of the solu-
tion in the articular cartilage. The freezing point can be calculated
using [30]
T0FP  TFP ¼

W1

s0L1  s0S1
	
RT0FPp
1þ

W1

s0L1  s0S1
	
Rp
(7)
where T0FP is the freezing point of pure water (273.15 K), TFP is the
freezing point of the solution (K), W1 is the molar mass of water
(0.01802 kg/mol), s0L1 and s
0S
1 are the molar entropies of pure liquid
water and of pure water in the solid phase, respectively (s0L1  s0S1
¼ 22.00 J/mol K), R is the universal gas constant (8.314 J/mol K), and
p is osmolality of the solution (osmol/kg solvent). The osmolality p
is calculated using Equation (5), where mi (mol solute/kg solvent)
are calculated as a function of water density and cryoprotectant
molar concentration, molar mass, and density. Osmolality varies as
a function of distance from the solution boundary, and thus the
freezing point temperature will also vary.6. Experimental results
Three vitriﬁed osteochondral dowels and two fresh control
dowels from 5 different patients were used with average articular
cartilage thicknesses of the three vitriﬁed dowels being 2.98 mm,
2.12 mm, and 2.08 mm (Samples 1, 2, and 3), respectively. Results
for cryoprotectant efﬂux during the ﬁrst and second immersions for
the experimental group are shown in Fig. 3. In the ﬁrst immersion,
the initial rate of change in osmolality of the removal solution per
N. Shardt et al. / Cryobiology 73 (2016) 80e9284dowel volume of all three vitriﬁed dowels was rapid. Subsequently,
the rate of change in osmolality slowed with time until a plateau
was reached. This recurred in the second immersion but with a
smaller change in osmolality and a lower plateau. The plateau was
considered to be reached when the change in osmolality of the
removal solution was less than the change in osmolality of the
control samples. Immersing the fresh dowels from the control
group resulted in minimal changes in the osmolality of the removal
solution (0e27 mOsmol/(kg mL)).
7. Theoretical results
7.1. Concentration proﬁles
Contour plots of the calculated concentration proﬁles using the
2-D model for each of the four loading steps of the DGPE vitriﬁ-
cation protocol are shown in Fig. 4 for an articular cartilage disc
thickness of 2.00 mm. These proﬁles illustrate the variation in
concentration as a function of radius and thickness for a slice
through the center of the cartilage dowel. Figs. 5e7 show the
calculated concentration proﬁle using the 2-D theoretical model as
a function of thickness at r ¼ 0 for Samples 1, 2, and 3, respectively.
7.2. Average concentrations
The concentrations of each cryoprotectant averaged over the
entire cartilage dowel using the 2-Dmodel for Samples 1 to 3 at the
end of the fourth loading step are summarized in Table 2. The
average total concentration of cryoprotectants over the whole
dowel at the end of the fourth loading step is also listed for each
sample. Table 3 shows the total concentration of cryoprotectants at
the surface, middle, and boneecartilage junction for Samples 1 to
3 at the center of the cartilage dowel (r¼ 0) after the fourth loading
step using the 2-D model.
7.3. Theoretical efﬂux
The theoretical predictions of the cryoprotectant efﬂux process
are shown in Figs. 8 and 9. Note that the cartilage discs had been
removed from the bone before immersion in the removal solution
for the efﬂux experiments, and efﬂux therefore occurs from both
surfaces at x ¼ 0 and x ¼ a and this was taken into consideration in
efﬂux calculations. Fig. 8 illustrates how the cryoprotectants diffuse
out of Sample 1 in the ﬁrst immersion at r ¼ 0. The spatial con-
centration proﬁle of each cryoprotectant inside the cartilage isFig. 3. Change in osmolality of the removal solution, normalized to the articular
cartilage disc volume, during the ﬁrst and second immersions of the experiment for
three samples.shown at times of 1 min, 5 min, 10 min, and 30 min. In Fig. 9, the
theoretical efﬂux of each cryoprotectant from Sample 1 for the ﬁrst
immersion is plotted. The total change in osmolality per volume of
dowel was predicted using Equation (5) and is illustrated by the
solid line.
As seen in Fig. 10(aec), the solid line represents the theoretical
prediction of the total cryoprotectant efﬂux from cartilage discs as
calculated according to Fick’s law of diffusion. The data points show
the experimentally measured values of osmolality in the X-VIVO
solution. The percentage error between the ﬁnal amount of cryo-
protectants efﬂuxed in the experiment and the expected amount as
predicted by the theoretical model is shown in Table 4 for each of
the three samples.
8. Theoretical shortening of the vitriﬁcation protocol
In the original protocol [20], each loading step was designed to
individually achieve the targeted minimum concentration of the
cryoprotectant at the boneecartilage junction. The original pro-
tocol’s concentration (Equation (6)) and freezing point temperature
(Equation (7)) proﬁles can be seen in Fig. 11(aed) for a cartilage
thickness of 2.00 mm using the 1-D representation of Fick’s law. In
the ﬁrst loading step, the Me2SO reaches 2.4 M at the bone-
ecartilage junction, and the concentration gradually increases
closer to the cartilageesolution boundary. As the cartilage is placed
in the second loading solution containing a maintenance concen-
tration of Me2SO, the concentration proﬁle ﬂattens, and for the
remaining loading steps, a relatively uniform proﬁle of Me2SO is
observed. We can take advantage of this equilibrating process that
occurs over the second to fourth loading steps to shorten the time
needed for the ﬁrst loading step and in fact, remove this step
entirely, as seen in the shortened protocol proposed below. Simi-
larly, we can shorten the time needed for the second and third
loading steps due to the equilibration of glycerol and PG that occurs
over the subsequent steps. To achieve this shortening, Fick’s law
will be used in 1-D for a 2-mm thick cartilage sample to permit the
successful vitriﬁcation of a wide range of cartilage surface areas.
In addition to cryoprotectant concentration, an appropriate
temperature for each loading step of a successful vitriﬁcation pro-
tocol must be determined. In the original protocol consisting of four
loading steps, the temperatures were 0 C, 0 C,10 C, and15 C,
respectively. The temperatures of the third and fourth steps were
chosen to be 2 C greater than the freezing point temperature at the
boneecartilage junction in the previous step so that ice formation is
avoided. For the ﬁrst iteration of optimization, we consider the
same temperatures as used in the original protocol for each loading
step.
As outlined in the original protocol [20], the minimum total
cryoprotectant concentration needed for successful vitriﬁcation is
6.5 M. Due to the toxicity and toxicity interactions of cryoprotec-
tants, this total 6.5 M concentration was split between 2.4375 M
Me2SO, 1.625 M glycerol, 0.8125 M PG, and 1.625 M EG, and it is
these individual concentrations that are desired for the shortened
protocol. Since each consecutive loading step impacts the ﬁnal
concentration proﬁle of the ﬁrst three loaded cryoprotectants, the
last step is optimized ﬁrst. For the fourth loading step, a time of
140 min is needed to achieve at least 1.625 M EG at the bone-
ecartilage junction. This was calculated by iteratively increasing
the time by 10 min.
Since the equilibration of Me2SO is rapid, the concentration of
the original ﬁrst loading step is decreased from 6 M to 3 M Me2SO
for the optimization calculations. The ﬁrst three loading steps were
given all possible times between 30 min and 230 min in MATLAB,
and the combinations of times that yield a total cryoprotectant
concentration greater than 6.5 M at the boneecartilage junction
Fig. 4. Contour plots of the concentration distribution as a function of thickness and radius calculated for a cartilage disc with a ¼ 2 mm and Rc ¼ 5 mm for the original vitriﬁcation
protocol at the end of each loading step for Me2SO, glycerol, PG, and EG using the 2-D model.
Fig. 5. Concentration proﬁles calculated using the 2-D model for the loading of Sample 1 (2.98 mm thick) at r ¼ 0; (a) the concentration distribution of Me2SO over the thickness of
the dowel after the ﬁrst loading step time of 1 h 30 min. (b) the distribution of Me2SO and glycerol after the second loading step time of 3 h 40 min. (c) the distribution of Me2SO,
glycerol, and PG after the third loading step time of 3 h. (d) the distribution of Me2SO, glycerol, PG, and EG after the fourth loading step time of 1 h 20 min.
N. Shardt et al. / Cryobiology 73 (2016) 80e92 85were identiﬁed. Out of these identiﬁed combinations, those with
individual concentrations greater than 2.3 MMe2SO, 1.5 M glycerol,
and 0.7 M PG were selected, so that the values were close to the
previously outlined 2.4375 M Me2SO, 1.625 M glycerol, and
0.8125 M PG. Several possible combinations of times satisﬁed these
requirements with a minimum total loading time of 7 h 20min. The
calculated ﬁrst loading step times were at the lower end of the
examined range (30e40 min), and any further decrease of this
amount could be balanced by increasing the time of the second
loading step since the temperature remains constant between
these two loading steps. Ultimately, the ﬁrst loading step could be
removed. Since the Me2SO concentration in the second solution is
only 2.4375 M and not the 3 M of the optimized ﬁrst loading so-
lution, an extra 10 min was needed for the second solution to
ensure that a minimum of 2.3 M Me2SO was present at the bone-
ecartilage junction by the end of the last step.A total loading time of 7 h 30 min was needed to achieve the
desired minimum individual and total cryoprotectant concentra-
tions if the ﬁrst loading stepwas removed. After the ﬁrst iteration of
optimization, the vitriﬁcation protocol consisted of three loading
steps: i) a solution of 2.4375 M Me2SO and 6 M glycerol for 3 h
30 min at 0 C, ii) a solution of 2.4375 M Me2SO, 1.625 M glycerol,
and 6 M PG for 1 h 40 min at 10 C, and iii) a solution of 2.4375 M
Me2SO, 1.625 M glycerol, 0.8125 M PG, and 6 M EG for 2 h 20 min at
15 C. However, the freezing point temperature at the bone-
ecartilage junction was not depressed sufﬁciently for the second
and third loading steps to take place at 10 C and 15 C,
respectively. As a result, the temperature of these loading steps
must be increased. This temperature increase will accelerate the
diffusion process, and this means that the time of the process can
be further reduced. Temperatures that were 2 C above the freezing
point at the boneecartilage junction were selected for the second
Fig. 6. Concentration proﬁles calculated using the 2-D model for the loading of Sample 2 (2.12 mm thick) at r ¼ 0; (a) the concentration distribution of Me2SO over the thickness of
the dowel after the ﬁrst loading step time of 1 h 30 min. (b) the distribution of Me2SO and glycerol after the second loading step time of 3 h 40 min. (c) the distribution of Me2SO,
glycerol, and PG after the third loading step time of 3 h. (d) the distribution of Me2SO, glycerol, PG, and EG after the fourth loading step time of 1 h 20 min.
Fig. 7. Concentration proﬁles calculated using the 2-D model for the loading of Sample 3 (2.08 mm thick) at r ¼ 0; (a) the concentration distribution of Me2SO over the thickness of
the dowel after the ﬁrst loading step time of 1 h 30 min. (b) the distribution of Me2SO and glycerol after the second loading step time of 3 h 40 min. (c) the distribution of Me2SO,
glycerol, and PG after the third loading step time of 3 h. (d) the distribution of Me2SO, glycerol, PG, and EG after the fourth loading step time of 1 h 20 min.
N. Shardt et al. / Cryobiology 73 (2016) 80e9286and third loading steps, and the previously outlined optimization
process was carried out to achieve the desired minimum cryopro-
tectant concentrations at these new temperatures. After this opti-
mization, the chosen temperatures were conﬁrmed to still beadequate for vitriﬁcation (i.e. 2 C greater than the freezing point at
the boneecartilage junction).
The ﬁnal optimized vitriﬁcation protocol consists of three
loading steps i) a solution of 2.4375 M Me2SO and 6 M glycerol for
Table 2
Calculated concentration (M) of cryoprotectants averaged over the entire cartilage disc after loading step 4 of the original vitriﬁcation protocol for all samples.
Cryoprotectant Me2SO (M) Glycerol (M) PG (M) EG (M) Average total cryoprotectant concentration (M)
Sample 1
2.98 mm
2.42 2.01 1.74 2.89 9.06
Sample 2
2.12 mm
2.43 2.21 1.97 3.38 9.99
Sample 3
2.08 mm
2.41 2.21 1.98 3.36 9.96
Table 3
Calculated total concentration (M) of cryoprotectants at the surface, middle, and boneecartilage junction for r ¼ 0 after loading step 4 of the original protocol for all cartilage
discs.
Total cryoprotectant concentration at
surface for r ¼ 0 (M)
Total cryoprotectant concentration at middle
for r ¼ 0 (M)
Total cryoprotectant concentration
at bone for r ¼ 0 (M)
Sample 1
2.98 mm
10.88 6.36 3.92
Sample 2
2.12 mm
10.88 8.52 6.30
Sample 3
2.08 mm
10.88 8.53 6.44
N. Shardt et al. / Cryobiology 73 (2016) 80e92 873 h 30 min at 0 C, ii) a solution of 2.4375 M Me2SO, 1.625 M
glycerol, and 6 M PG for 1 h 30 min at 7 C, and iii) a solution of
2.4375 M Me2SO, 1.625 M glycerol, 0.8125 M PG, and 6 M EG for
2 h at 10 C.
The optimization results in a vitriﬁcation protocol that is 2.5 h
shorter yet maintains the minimum concentration previously
shown to result in successful vitriﬁcation [20] throughout the
cartilagematrix and reduces the possibility of ice formationwith an
appropriate selection of loading step temperatures. This is a theo-
retical vitriﬁcation protocol that has not been proven to maintain
cell viability. Fig. 11 shows the concentration proﬁles for the orig-
inal and modiﬁed loading steps and the predicted freezing point
temperatures as calculated by the 1-D model. The shorter times
identiﬁed from this 1-D optimization were then used to predict the
concentration contours for a 2-D cartilage disc with a 2-mm
thickness and 5-mm radius, as shown in Fig. 12. The modiﬁed
protocol in Fig. 12 can be directly compared with the original pro-
tocol in Fig. 4. Table 5 summarizes the desired cryoprotectant
concentrations with the boneecartilage junction concentrations of
each cryoprotectant for the original and the modiﬁed protocols. For
themodiﬁed protocol, it can be seen that the ﬁnal concentrations of
Me2SO, glycerol, PG, and EG at the boneecartilage junction are
close to the desired values, and the total cryoprotectant concen-
tration is greater than the minimum 6.5 M needed for successful
vitriﬁcation.
9. Discussion
Understanding the kinetics of cryoprotectant loading and efﬂux
into and out of intact articular cartilage is valuable information for
designing loading and unloading steps during the process of pre-
paring vitriﬁed cartilage tissue for subsequent transplantation.
Our previously published vitriﬁcation protocol [20] was
designed speciﬁcally using permeation kinetics for individual
cryoprotectants determined in pig articular cartilage permeation
studies [4,21,31]. The diffusion coefﬁcients were assumed to be
reasonable approximations of those for human articular cartilage
and were used to estimate the exposure times required during the
vitriﬁcation protocol to get the desired concentration of each
cryoprotectant at the boneecartilage junction of the tissue to be
vitriﬁed. The times were based on calculations performed for 2-mmthick articular cartilage. These assumptions proved to be practically
useful as we have been able to use this information to successfully
vitrify human articular cartilage [20]. In the current study, we
endeavored to verify that reasonable predictions of efﬂux from
vitriﬁed human articular cartilage could bemade using a number of
simplifying assumptions: i) diffusion coefﬁcients measured from
permeation experiments could be used to predict efﬂux, ii) diffu-
sion coefﬁcients measured for individual cryoprotectants could be
used to predict diffusion of combined cryoprotectants, iii) diffusion
coefﬁcients measured for porcine articular cartilage could be used
to make predictions for human articular cartilage of various thick-
nesses, and iv) simplifying the diffusion calculations by using Fick’s
law would not lead to large errors.
In the experiments, as expected, there was an initial rapid efﬂux
of the cryoprotectants out of the tissue after immersion in the
washing solution that slowed with time. A small amount of the
cryoprotectants remained even after the initial 24 h and was
removed with the second wash. This remaining cryoprotectant
within the tissue even after 24 h supports our recommended
method of clinical cryoprotectant removal using multiple short
washes with fresh washing solution [36].
The theoretical prediction of cryoprotectant efﬂux from human
articular cartilage after the tissue had come to equilibriumwith the
ﬁrst immersion solution agreed with the measured amount within
a maximum of 15% error (Fig. 10 and Table 4). The predicted efﬂux
in the ﬁrst immersion for each samplewas greater than the amount
efﬂuxed experimentally. This means that the theoretically-
calculated cryoprotectant concentration proﬁle initially in the
cartilage (or equivalently, at the end of the loading steps in the
vitriﬁcation protocol) is greater in magnitude than the actual con-
centration proﬁle within the cartilage disc. This is unexpected
because the theoretical model of Fick’s law is known to underes-
timate the actual permeation of cryoprotectants in porcine articular
cartilage [1]. The fact that the theoretical model overestimates
experimental efﬂux measurements therefore suggests that the
effective Fick’s law diffusion coefﬁcients for cryoprotectants in
porcine articular cartilage are greater than the Fick’s law diffusion
coefﬁcients in human cartilage; this conclusion is supported by
experimental evidence that the permeability of human articular
cartilage is lower than that of porcine articular cartilage [32]. In
addition to the different mechanical properties of porcine and
Fig. 8. Cryoprotectant concentration calculated using the 2-D model inside the carti-
lage disc during efﬂux as a function of axial position at r ¼ 0 in Sample 1 at times of (a)
1 min, (b) 5 min, (c) 10 min, and (d) 30 min during the ﬁrst immersion.
Fig. 9. Breakdown of cryoprotectant efﬂux from Sample 1 for the ﬁrst immersion.
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different thicknesses of cartilage since cartilage is not ahomogenous structure. As the cartilage thickness changes, the
distributions of its constituents vary and may result in different
diffusion coefﬁcients.
To enhance the understanding of what is happening within the
cartilage matrix, spatial distributions of cryoprotectant concentra-
tions within the cartilage matrix after each step of our original
vitriﬁcation process were calculated using Fick’s law of diffusion
and are shown in Figs. 5e7. The ﬁnal concentration at the bone-
ecartilage junction will vary depending on the thickness of the
cartilage because the permeation times in the protocol were
determined speciﬁcally for a standard 2-mm thick tissue as
opposed to custom designed for each sample. Thus, the 2.98-mm
thick tissue will have less than 6.5 M total cryoprotectant concen-
tration at the boneecartilage junction, while the 2.12-mm and
2.08-mm thick samples have concentrations close to 6.5 M at the
boneecartilage junction (Table 3). In addition, cryoprotectant
concentrations spatially averaged over the whole tissue were
calculated at the end of the fourth loading step and are given in
Table 2. Designing the loading protocol to achieve 6.5 M total
cryoprotectant concentration at the boneecartilage boundary re-
sults in a substantially higher overall cryoprotectant concentration
at the end of loading due to the spatial inhomogeneity of the
diffusion driven loading process.
At the cartilage surface, the last cryoprotectant to be added (EG)
remains at its initial loading concentration (6 M) at the cartilage
surface, with concentration reducing as the depth increases. Even
though the third cryoprotectant to be added (PG) is at the ﬁnal
solution concentration at the cartilage surface, just 1 mm in from
this surface, the concentration remains higher than designed
because of insufﬁcient time to equilibrate. The concentration of
glycerol throughout the cartilage thickness becomes progressively
higher from the cartilage surface to the boneecartilage junction
and is consistently greater than the designed concentration. These
observations could have important ramiﬁcations during the vitri-
ﬁcation process. The high cryoprotectant concentrations at the
surface in all samples leave the cells in these areas at higher risk for
cryoprotectant toxicity. This is in effect until a depth of approxi-
mately 1 mmwhere the concentrations are progressively lower. At
the boneecartilage junction, if the tissue is close to 2 mm thick, it
can be assumed that the total cryoprotectant concentration is close
to 6.5 M. But, as the tissue increases in thickness, the concentration
at the boneecartilage junction will decrease, leaving cells in this
area at risk for ice formation during the cooling or warming pro-
cess. The “average” concentrations shown in Table 2 can be
misleading. All samples had an average total cryoprotectant con-
centration greater than the 6.5 M targeted for 2-mm thick cartilage
samples. This was because the cryoprotectant concentration was
just slightly below 6.5 M at the boneecartilage junction for each
experimental sample, while the cryoprotectant concentration
Fig. 10. Predicted and experimental efﬂux of all cryoprotectants from (a) Sample 1, (b)
Sample 2, and (c) Sample 3 with thicknesses of 2.98 mm, 2.12 mm, and 2.08 mm,
respectively.
Table 4
The percentage error between the theoretical predictions and the experimental result
immersion.
Theoretical 24 h (mOsm/(kg mL))
Sample 1
2.98 mm
2245
Sample 2
2.12 mm
2481
Sample 3
2.08 mm
2482
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marizes the total cryoprotectant concentrations at the surface, in
themiddle of the tissue, and at the boneecartilage junction for each
sample.
The issue of toxicity is paramount due to the high cryopro-
tectant concentration in the cartilage closest to the solution, and
this is addressed with the new shorter vitriﬁcation protocol pre-
sented herein. This shortened version has not been proven to be
effective at maintaining cell viability but demonstrates that nearly
equivalent concentrations can be achieved at the bone-cartilage
junction in a signiﬁcantly shorter time period. The excess PG
shown in Fig. 11(d) above the minimum 0.8125M is reduced in the
modiﬁed shorter protocol. Fig. 11(g) shows that by the end of the
modiﬁed last loading step, the concentration proﬁle of PG is
relatively uniform at the targeted value of 0.8125 M. The ﬁnal
spatial distributions of Me2SO, glycerol and EG are relatively un-
changed, but the cells closer to the solution are still exposed to
high concentrations of cryoprotectant over the duration of the
protocol. However, it is important to note that decreasing the
duration of the loading steps lowers the risk of toxic exposure of
the cells to the cryoprotectants. The removal of the ﬁrst loading
step further decreases toxicity risk since the exposure to 6 M
Me2SO has been eliminated, while still achieving a 2.3 M Me2SO
concentration by the end of the protocol. The overall effect is a
decrease in cryoprotectant exposure and a maintenance of the
minimum total 6.5 M cryoprotectant concentration throughout
the articular cartilage, as summarized in Table 5.
10. Conclusions
This study suggests that the permeation and efﬂux kinetics of
cryoprotectants in human articular cartilage are similar to those in
porcine articular cartilage. The permeation and efﬂux of cryo-
protectants into and out of articular cartilage during the vitriﬁ-
cation process is complex with spatially and temporally varying
concentrations throughout the matrix that could have important
effects on the cell viability. Transport simulations are a key tool in
understanding the kinetics of permeation and efﬂux, and this may
help in optimizing cryoprotectant addition and removal pro-
cesses. The optimization methods outlined in this study can be
extended to other cryoprotectant solutions and multi-step vitri-
ﬁcation procedures for other biologic tissues if the mass transfer
properties of the cryoprotectant solution in the structure are
known.
Previous work developed a vitriﬁcation protocol based on
criteria of cryoprotectant concentration, cryoprotectant toxicity,
and freezing point temperature; it was successful when tested on
intact human articular cartilage [20]. The current study shortened
this protocol by 2.5 h while still achieving the minimum necessary
cryoprotectant concentration at the boneecartilage junction as
outlined in the established protocol and taking place at appropriate
temperatures that are predicted to avoid ice formation. It should be
clearly stated that the effectiveness of this shortened protocol iss for the three samples (cartilage discs excised from bone) at the end of the ﬁrst
Experimental 24 h (mOsm/(kg mL)) Percentage error (%)
2057 9.1
2352 5.5
2157 15.1
Fig. 11. Concentration proﬁles and freezing point temperature proﬁles calculated at the end of each loading step for a 2-mm slab using the 1-D model for the original vitriﬁcation
protocol (aed) and the new shortened vitriﬁcation protocol (eeg); (e) the distribution of Me2SO and glycerol after the modiﬁed ﬁrst loading step time of 3 h 30 min at 0 C. (f) the
distribution of Me2SO, glycerol, and PG after the modiﬁed second loading step time of 1 h 30 min at 7 C. (g) the distribution of Me2SO, glycerol, PG, and EG after the modiﬁed third
loading step time of 2 h at 10 C.
Fig. 12. Contour plots of the concentration distribution as a function of thickness and radius calculated for a cartilage disc with a ¼ 2 mm and Rc ¼ 5 mm for the shortened
vitriﬁcation protocol at the end of the modiﬁed loading steps for Me2SO, glycerol, PG, and EG. These plots were calculated by using the 2-D model with the shorter times previously
identiﬁed in the 1-D optimization.
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Table 5
Calculated cryoprotectant concentrations (M) at the boneecartilage junction at r¼ 0
after the end of the original cryoprotectant loading protocol and after the end of the
modiﬁed shortened loading protocol for a 2-mm thick cartilage disc with Rc¼ 5 mm
as calculated by the 2-D model.
Cryoprotectant BoneeCartilage junction concentration
Desired (M) Original protocol (M) Modiﬁed protocol (M)
Me2SO 2.4375 2.46 2.37
Glycerol 1.625 2.47 2.39
PG 0.8125 1.25 0.88
EG 1.625 0.63 1.69
Total 6.50 6.81 7.33
N. Shardt et al. / Cryobiology 73 (2016) 80e92 91theoretical at this time and has not been shown to provide similar
results to the previously described protocol. If this shortened pro-
tocol proves to be clinically effective, it would decrease the
time needed for vitriﬁcation from 9.5 h to 7 h; this is signiﬁcant,
because only one personnel shiftdwith no overtimedwould now
be required in a tissue bank, reducing the costs involved and
enabling the same person to perform the whole protocol for con-
sistency purposes although it is acknowledged that signiﬁcant
preparation work would need to be performed by another staff
member prior to the actual vitriﬁcation process. The optimization
of the protocol thus encourages clinical use of articular cartilage
vitriﬁcation previously shown to be effective at preserving some
cell viability [20].
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